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Instillation and Hydrodistention in Patients with Refractory 
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Purpose: Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disabling disease of the urinary bladder, and its etiology and 
treatment are not yet established. Current medications used in the treatment of PBS/IC have shown limited efficacy. This pro-
spective study investigated the efficacy of intravesical resiniferatoxin (RTX) in PBS/IC refractory to medical treatment.
Methods: Patients with proven PBS/IC refractory to traditional medical treatment were enrolled. By randomized trial, a total of 
18 consecutive patients were divided into two groups: treatment with hydrodistention and intravesical RTX (group 1) or treatment 
with hydrodistension only (group 2). We assessed bladder pain by use of a visual analogue pain scale, the maximal urine flow rate, 
post-void residual urine volume , and a voiding diary before and 3 months after treatment. 
Results: The median age of the 18 patients was 55.8±6.9 years, and the median duration of symptoms before diagnosis was 3.6±
1.6 years. Frequency, functional bladder capacity, and score on a 5-point pain scale were significantly improved at 3-month after 
treatment in both groups. Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have 
a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale.
Conclusions: Intravesical RTX instillation plus hydrodistention was effective in relieving pain but was not effective in improving 
lower urinary tract symptoms. Further larger studies are needed to clarify the efficacy of combination treatment of intravesical 
RTX instillation and hydrodistention. 
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INTRODUCTION
Interstitial cystitis (IC) is a chronic, disabling disease that is char-
acterized by bladder pain, urgency, and frequency. IC was origi-
nally described by Hanash and Pool as a condition with severe 
urinary symptoms, reduced bladder capacity and typical cysto-
scopic findings of ulcer [1]. The diagnosis is made clinically and 
is confirmed by cystoscopy with hydrodistention and often by 
biopsy for exclusion of other pathologies. Controversies remain, 
however, over the definition, pathophysiology, and standard 
treatment of IC. 
  In 1987, the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) proposed diagnostic criteria that are 
mainly based on exclusions [2], and that have been found to be 
too restrictive for clinical use. Recently, the European Society 
for the Study of Interstitial Cystitis proposed a new nomencla-
ture and classification system [3]. Because pain is the fundamen-
tal feature of the condition, it was proposed that the name be 
changed to painful bladder syndrome (PBS).
  Vanilloids modulate the activity of sensory neurones. Resin-
iferatoxin (RTX) is an ultra-potent analogue of the chilli pepper 
extract capsaicin, that causes less pain on instillation and is there-
Original Article
http://dx.doi.org/10.5213/inj.2012.16.1.41
pISSN 2093-4777 · eISSN 2093-693142    www.einj.org
Ham, et al.  •  Intravesical Resiniferatoxin Instillation
http://dx.doi.org/10.5213/inj.2012.16.1.41
INJ
fore easier to use. However, the treatment outcome of RTX re-
mains contradictory.
  Refractory PBS/IC is defined as persistent, unacceptable 
symptoms despite oral or intravesical therapy. According to the 
2010 IC guidelines [4], more aggressive modalities such as hy-
drodistention, neuromodulation, and intravesical botulinum 
toxin are recommended for refractory PBS/IC. Although hy-
drodistention, which is a common treatment, is included as an 
interventional treatment, there are limitations in its scientific 
basis [5].
  The primary aim of this study was to investigate the safety 
and effectiveness of the combination therapy of intravesical RTX 
instillation and hydrodistention in patients with refractory PBS/
IC. To our knowledge, this is the first randomized trial of intra-
vesical RTX instillation and hydrodistention. 
MATERIALS AND METHODS
This study was part of a prospective, longitudinal, observational 
study. Eighteen women who met the NIDDK consensus research 
criteria for IC and were refractory to classic medical treatment 
were studied. By randomized trial, all patients were divided into 
two groups: treatment with hydrodistention and intravesical 
RTX (group 1, n=8) or treatment with hydrodistension only 
(group 2, n=10). Informed consent was obtained from each 
subject, who were advised of the potential adverse effects of hy-
drodistention and intravesical RTX instillation, and the study 
was approved by the Institutional Review Board. Before treat-
ment, a voiding diary, uroflowmetry parameters, and visual an-
alogue pain scale (VAS) scores were recorded. VAS scores and a 
3-day voiding diary were recorded at 1 month and 3 months af-
ter treatment. The endpoint of this study was the recurrence of 
pain that required treatment, including medical or interven-
tional treatment.
  The combination treatment of RTX intravesical instillation 
and hydrodistention was done under general anesthesia. The 
method of hydrodistention as follows. The bladder was filled 
with solution (300 mL/pack of 3% D-sorbitol solution; Baxter, 
Deerfield, IL, USA) to 80 cm H2O. Drop speed was approxi-
mately 30 mL/min. During the procedure, the cystoscope was 
fixed at the back or side walls. The bladder was filled until it be-
gan to leak from the urethra around the cystoscope. At that time, 
the liquid was let out. The cystoscope was fixed at the same po-
sition and dropping was stopped. The liquid was discharged 
slowly from the bladder at 30 mL/min and and the procedure 
was carefully repeated. The expected goal of bladder capacity 
was 400 mL or 500 mL. If the functional bladder capacity (FBC) 
was <200 mL, the expected goal for bladder capacity was 400 
mL, and if FBC was more than 200 mL, the expected goal for 
bladder capacity was 500 mL. 
  All RTX doses were administrated as a 10% ethanolic solu-
tion. Fifty milliliters of the drug solution was administrated af-
ter complete urine drainage. RTX was administrated through a 
silicon urinary catheter and was held in the bladder for 30 min-
utes. Then the bladder was drained and irrigated with normal 
saline. A new urethral Foley catheter was indwelled overnight.
  The vital signs of the patients were checked regularly during 
the procedures. The urethral Foley catheter was removed on the 
second day after the operation, and the patient was discharged 
on the third day.
  The primary outcome measures assessed were preoperative 
and postoperative average frequency, average bladder volume 
from a 3-day voiding diary, and VAS score (patients were asked 
to grade the severity of pain on a linear scale from 0 to 5 with 0 
meaning no pain and 5 meaning the worst pain). Therapeutic 
outcome was judged to be positive when pain was relieved at 3 
months of follow-up and no aggravation or new occurrence of 
bladder pain was noted through 3 months of follow-up. Recur-
rence was judged to be a condition in need of treatment such as 
medication or interventional treatment to control bladder pain.
  Statistical analysis was performed by using SPSS ver. 18.0 
(SPSS Inc, Chicago, IL, USA). Data are reported as mean values 
with standard deviations, because normality of the distribution 
of continuous variables was proven by the Kolmogorov-Smirnov 
test. Comparisons between preoperative and postoperative   
data were performed by use of the Wilcoxon signed-rank test 
and the Pearson chi-square test. To identify the variables affect-
ing recurrence and pain aggravation, the Mann-Whitney U test 
was conducted.
RESULTS 
The median age of the 18 patients was 55.8±6.9 years and the 
mean duration of symptoms before diagnosis was 3.6±1.6 years. 
There were no clinically meaningful differences among the two 
groups in the severity of IC symptoms. All patients had under-
gone previous therapy to control their symptoms without a 
beneficial effect. The characteristics of the patients in each group 
before treatment are described in Table 1.
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follow-up in either group, but scores on the 5-point pain scale 
showed improvement at both 1 month and 3 months follow-up 
in group 1 (Table 2, Fig. 1). There were no significant differences 
in nocturia, maximal urine flow rate, or post-void residual urine 
volume (Table 2). 
  Frequency showed improvement at 1 month in both groups 
(P=0.02, 0.03, respectively), but did not show improvement at 
3 months (Fig. 2). FBC showed improvement at 1 month in 
both groups (P=0.02, 0.03, respectively), but did not show im-
provement at 3 months (Fig. 3). Bladder pain was significantly 
relieved at both 1 month and 3 months of follow-up in group 1 
(P=0.022, 0.041, respectively), but was relieved only at 1 month 
Table 1. Characteristics of the patients in the two groups 
Characteristic
Group 1  
(n=8)
Group 2  
(n=10)
P-value
Age (yr) 54.5±9.1 56.9±7.8 0.81
Duration of IC symptoms (yr)  3.5±1.5 3.8±1.3 0.77
Duration of previous Tx (yr) 2.8±1.6 3.0±1.8 0.64
Frequency (/day) 16.8±6.7 15.6±7.6 0.76
Nocturia (/night) 4.4±1.7 4.4±2.5 0.72
Pain score 3.3±0.8 3.5±1.1 0.67
FBC (mL) 210.4±34.7 239.0±36.0 0.21
Qmax (mL/sec) 14.8±5.7 16.3±6.7 0.71
PVR (mL) 15.0±19.4 14.2±13.8 0.97
Values are presented as mean±standard deviation. 
IC, interstitial cystitis; Tx, treatment; FBC, functional bladder capacity; 
Qmax, maximal urine flow rate; PVR, post-void residual urine volume.
Table 2. Changes from before treatment to the 3 months follow-
up after treatment in the two groups
Parameter Group 1 (n=8) Group 2 (n=10) P-value
a)
NO. of frequency (/day)
Baseline 16.8±6.7 15.6±7.6
After 3 mo 15.4±2.9 14.8±6.0
Delta -0.4±4.1 -6.6±2.5 >0.05
P-value
b) >0.05 >0.05
No. of nocturia (/night)
Baseline 4.4±1.7 4.4±2.5
After 3 mo 3.6±1.5 3.1±1.4





After 3 mo 2.9±0.4 3.3±0.7





After 3 mo 222.9±36.9 242.0±50.2





After 3 mo 15.2±5.4 16.2±5.4





After 3 mo 13.8±11.8 13.2±9.6
Delta -1.2±17.6 -1.0±4.2 >0.05
P-value
b) >0.05 >0.05
Values are presented as mean±standard deviation. 
FBC, functional bladder capacity; Qmax, maximal urine flow rate; 
PVR, post-void residual urine volume.
a)P-value by Mann-Whitney U test. 
b)P-value was analyzed by Wilcoxon 
signed rank test.
of follow-up in group 2 (P=0.031) (Fig. 1).
  No serious adverse effects (bladder rupture, sepsis) occurred 
after the treatments, but hematuria (2 patients in group 1) and 
bladder pain (1 patient in group 2) occurred. These side effects 
disappeared within 2 days. 
Fig. 1. Differences in pain scores between baseline and 1 month 
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PBS/IC is a chronic inflammatory disease that causes symptoms 
of pain in the bladder or pelvis with or without urgency, fre-
quency, and nocturia [6]. The prevalence in women was esti-
mated at around 18.1 cases per 100,000 females in a Finnish 
survey. The prevalence in both sexes is 10.6 cases per 100,000 
persons with the annual incidence of new cases being 1.2 cases 
per 100,000 persons. Severe cases account for about 10% of the 
total and most studies show a female to male preponderance of 
5:1 or greater [7]. PBS impairs quality of life, causes sleep dys-
function, depression, and creates anxiety, sexual and social 
problems [8]. Treatment of PBS can be classified into conserva-
tive, oral medical therapy, intravesical drug instillation, neuro-
modulation and surgical therapy. Despite the many treatment 
strategies, there are no general standard treatments yet. Many 
drugs are used empirically, and only a few of them have been 
studied in randomized controlled trials. 
  Refractory PBS/IC is defined as persistent, unacceptable 
symptoms despite oral or intravesical therapy. According to the 
2010 IC guideline [4], more aggressive treatment modalities 
such as interventional treatment are recommended. 
  Hydrodistention of the bladder has been used for many years, 
not only for diagnosis but also for treatment of PBS [9], but re-
cent studies have reported poor results, with only a small num-
ber of patients reporting symptom improvement for only a short 
period of time [5,10]. Moreover hydrodistention has limitations 
in its scientific basis and could yield diverse adverse events in-
cluding both mild events (e.g., hematuria, bladder pain) and se-
rious events (e.g., bladder rupture, sepsis). According to the 2011 
American Urological Association guideline, high-pressure, long-
duration hydrodistention should not be offered (grade C rec-
ommendation) [11]. In our study, patients underwent hydro-
distention under direct observation by cystoscope after general 
anesthesia. To reduce adverse events by hydrodistention, the 
expected goal of bladder capacity was determined by consulting 
the patient’s individual voiding diary. If FBC was under 200 
mL, the expected goal for bladder capacity was 400 mL, and if 
FBC was more than 200 mL, the expected goal for bladder ca-
pacity was 500 mL.
  RTX is an ultra-potent analogue of the chilli pepper extract 
capsaicin, that causes less pain on instillation and is therefore 
easier to use. Vanilloids modulate the activity of sensory neu-
rons and pain-mediating C-fibers [12]. Studies have been con-
ducted on the vanilloid receptor-1, which is activated by vanil-
loid agonists, such as capsaicin or its analogue, RTX. The effica-
cy of RTX has been shown in small clinical trials [13,14], but 
different results were reported from two randomized, double-
blind, placebo-controlled studies conducted with instillation of 
a single dose of RTX in different concentrations [15,16]. In those 
two studies, both study groups were followed up for 3 months 
with evaluation several times. No significant improvement in 
symptoms was found in either of the trials, but both reported 
dose-dependent increases in instillation pain. Thus, until now, 
Fig. 2. Differences in frequency numbers between baseline and 




















Fig. 3. Differences in functional bladder capacity (mL) between 
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the treatment outcome of RTX has been various and contradic-
tory.
  Intravesical RTX instillation in idiopathic detrusor overactiv-
ity has recently been studied [17,18]. Considering the shared 
pathogenesis of the mediation of C-fibers between idiopathic 
detrusor overactivity and PBS/IC, these studies remind us of 
RTX treatment. Silva et al. [17] in their open-label study re-
ported the efficacy of a single 50 nM intravesical instillation of 
RTX, with improvement in clinical and urodynamic parame-
ters. Rios et al. [18] in their double-blind, randomized, placebo-
controlled trial, studied 50 nM intravesical RTX and reported 
no differences in efficacy compared with placebo. One proven 
fact concerning intravesical RTX treatment is that its short-
term outcome is favorable. This is why Peng and Kuo [19] stud-
ied the efficacy of multiple intravesical low-doses of RTX, 
which yield favorable efficacy in relieving lower urinary tract 
symptoms in refractory PBS/IC.
  In our study, intravesical RTX with hydroditention signifi-
cantly improved voiding symptoms and bladder pain in patients 
with refractory PBS/IC at 1 month of follow-up. However, no 
favorable outcomes on voiding symptoms were seen at 3 months. 
Bladder pain was relieved at 3 months, but longer follow-up is 
crucial for the evaluation of clinical efficacy. Our study was a 
pilot study and the first trial of combination therapy of intra-
vesical RTX instillation and hydrodistention.
  Our study did have some limitations. First, we could not de-
termine the effect of intravesical RTX instillation only compared 
with RTX plus hydrodistetion. Considering the dose of RTX, 
the effect of RTX could be small. Because of this being a pilot 
study, we could not examine a higher dose together with hydro-
distention. Second, the number of patients was small. Third, al-
though we designed a randomized pilot study, we did not use 
placebo instillation. However, the commonly used placebo ma-
terial, ethanol, affects bladder capacity and micturition pressure 
by itself. Also, considering the anesthesia state, the placebo ef-
fect could be minimal. Last, urodynamic study was not per-
formed of sensory and motor function of the bladder. Larger 
studies are needed, including higher-dose RTX treatment or re-
peated low-dose RTX in refractory PBS/IC. 
  In conclusion, intravesical RTX instillation plus hydrodisten-
tion was effective in relieving pain over hydrodistention only. 
Although the shorter term outcome of both treatments showed 
improvements in clinical efficacy, only the combination treat-
ment improved pain. Further larger studies are needed or other 
noninvasive combination methods must be devised to increase 
clinical efficacy in refractory PBS/IC. 
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